Cequent Pharmaceuticals, a Cambridge, Mass., developer of drugs based on a new gene-silencing technology, raised $9 million in a first-round funding. The round was led by the Novartis Option Fund, joined by Ampersand Ventures, Nexus Medical Partners, and Pappas Ventures.
Cequent is developing new treatments based on RNA interference, a Nobel Prize-winning technology that “silences” gene outputs using short stretches of RNA. Its first candidates, none of which have been tested in humans, are aimed at colon-cancer prevention and inflammatory bowel disease.
12:01 pm
VentureBeat » Life sciences briefing: Thursday, Feb. 7, 2008 said:
[...] cells and produce the desired RNA molecules locally. We covered Cequent’s previous funding here. For more stories on VentureBeat Life Sciences, click here.Tagged co:Cequent Pharmaceuticals, [...]
12:01 pm
VentureBeat » Life sciences briefing: Thursday, Feb. 7, 2008 said:
[...] cells and produce the desired RNA molecules locally. We covered Cequent’s previous funding here. For more stories on VentureBeat Life Sciences, click here.Tagged co:Cequent Pharmaceuticals, [...]